The formulation will be sold under the brand name Larither. Ipca will be the first company in India to manufacture this bulk drug. These products will help the company to record a good growth rate in future. The company is gradually reducing its dependence on the therapeutic category by focussing on other areassuch as cardiovascular. Having tied up with many foreign players has helped the company to become a global sourcing base for many of the bulk drugs and intermediates.
Intermediates account for a major part of the company's exports.
Ipca's ownership pattern has changed recently with film star Amitabh Bachchan and family selling most of their stake to the two managing directors whose holdings have crossed 50 per cent now. Only through innovations can the company catapult itself into the big league in the coming years.